Zetagen Therapeutics to Present Preliminary Results
Zetagen Therapeutics, a clinical-stage biopharmaceutical company, will present preliminary results from a Phase 2 clinical trial targeting metastatic breast cancer to bone.
The abstract, titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 10, 2025.
Author's summary: Zetagen presents results on breast cancer treatment.